Femasys Q1 net loss widens to $3.6M; sales down 8%; cash runway into H2 2025

FEMASYS INC

2024-Q1 EPS reported -$0.17 revenue$271,140

Net loss of $3.6M ($0.17 EPS) vs $2.9M ($0.25 EPS) in Q1 2023; sales $271K vs $294K.
R&D expenses rose 15% to $1.77M; G&A $1.50M; operating loss $3.46M.
Cash $17.8M; expects funding operations into second half 2025.
Positive topline data from FemaSeed pivotal trial; first commercial procedure completed.
Appointed Richard Spector as CCO; FemBloc pivotal trial enrollment initiated at six sites.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

FEMASYS INC reported first quarter ended March 31, 2024 results: revenue $271,140, net income $3,599,510, EPS $0.17.

Period: first quarter ended March 31, 2024
Revenue: $271,140
Net income: $3,599,510
EPS: $0.17
Result: reported results

Exact text from the filing

Quarter Ended March 31, 2024 • Research and development expenses increased by $233,292 to $1,770,731 in Q1 of 2024 from $1,537,439 in Q1 of 2023 • Sales decreased by $22,844 to $271,140 in Q1 of 2024 from $293,984 in Q1 of 2023 • Net loss was $3,599,510 or $0.17 per basic and diluted share attributable to common stockholders, for the quarter ended March 31, 2024,

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-24-025064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.